This is the authors' abstract. We don't add key points for this paper.
The World Health Organization (WHO) set the ambitious goal of eliminating hepatitis C virus (HCV) as a public health threat by 2030.1 To achieve this goal, the scale-up of direct-acting antiviral therapies (DAA) and the implementation of macroelimination and microelimination approaches are necessary cornerstones.2,3 A Spanish population-based study between 2015 and 2017 with 12,246 participants determined an anti-HCV prevalence of 1.2% (95% confidence interval [CI] 1.0–1.4), with a prevalence of viremia of 0.3% (0.2–0.4).
No takes yet. Share an insight, caveat, or question.
Alonso‐Peña et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: